Medical devices have changed a lot in the last few years. Many now connect with hospital networks, mobile apps, cloud platforms, and remote monitoring systems. While this has improved patient care, it has also created new security problems. Making compliance with the FDA cybersecurity checklist essential for manufacturers developing connected medical devices. Hospitals across the US have already faced ransomware attacks that affected connected medical systems and delayed critical care services.
This is one reason the FDA tightened cybersecurity requirements under Section 524B. After FDORA Section 524B, medical device companies are now expected to include security during development instead of treating it like a last-minute requirement before submission.
If you are planning to launch a medical device in the US market, then first understand the FDA cybersecurity checklist. This guide covers the main requirements, documents, and security areas you need to prepare for in 2026.
What Is FDA Medical Device Cybersecurity Compliance?
FDA medical device cybersecurity compliance is about making sure your device stays safe and secure before and after it reaches the market. The FDA expects manufacturers to reduce security risks that could affect patient safety, device performance, or sensitive healthcare data.
This process starts during product development itself. Companies are now expected to build security into the device from the beginning instead of treating it as a final step before submission.
The FDA also follows something called Total Product Lifecycle cybersecurity. This means manufacturers are responsible for security throughout the device’s lifecycle, including development, testing, release, updates, and vulnerability handling after deployment.
Premarket cybersecurity focuses on things like:
- Risk assessments
- Threat models
- Security testing
- SBOM documentation.
Postmarket responsibilities focus more on:
- Monitoring vulnerabilities
- Releasing patches
- Responding to newly discovered threats.
Under Section 524B, devices with software, internet connectivity, cloud communication, or data sharing capabilities are generally treated as “cyber devices.” Because of this, compliance now includes supplier oversight, software lifecycle management, risk management, and continuous monitoring, along with technical security controls.
Which Medical Devices Must Comply With FDA Cybersecurity Requirements?
FDA cybersecurity requirements apply to most modern medical devices that use software or programmable systems. If a device can connect, communicate, store data, or receive updates, the FDA will likely treat it as a cyber device under Section 524B.
In many cases, the following features bring a device under the FDA cybersecurity review:
- Internet or network connectivity
- Wireless communication, such as WiFi or Bluetooth
- Cloud-based functionality
- Remote access capabilities
- Mobile app integration
- Remote software or firmware updates
This applies to a wide range of healthcare technologies, including:
- Infusion pumps
- Imaging and diagnostic systems
- Implantable medical devices
- Patient monitoring systems
- Software as a Medical Device platforms
- Mobile health applications
- AI-based diagnostic tools
- Telehealth platforms
Even the smaller software components inside the device matter. Open source libraries, third-party tools, and supplier-provided software are all part of the FDA review process. If one vulnerable component creates a security risk, manufacturers are still responsible for addressing it.
FDA Cybersecurity Checklist for Medical Devices (2026)
1. Establish a Secure Product Development Framework (SPDF)
Many medical device companies used to focus on cybersecurity near the end of development, usually before testing or submission. The FDA no longer accepts that approach. Security now needs to be part of the entire software lifecycle, from early design decisions to post-release updates.
This is why SPDF has become such an important part of FDA cybersecurity reviews. The idea behind it is straightforward: catch security problems early, reduce avoidable vulnerabilities, and make sure the device stays secure after deployment as well.
The FDA often references standards and frameworks like:
- IEC 81001 5 1
- AAMI TIR45
- AAMI TIR57
- NIST SSDF
- ISA IEC 62443 4 1
A proper SPDF usually includes:
- Documented cybersecurity governance
- Defined ownership for security tasks
- Secure coding practices
- Architecture security reviews
- Least privilege access controls
- Security checks inside CI CD workflows
- Dependency and secret scanning
- SAST and DAST testing
- Penetration testing before release
- Security regression testing
- Vulnerability tracking processes
- Patch management procedures
2. Perform Cybersecurity Risk Management
FDA cybersecurity risk management closely connects with ISO 14971 because both focus on patient safety. The main difference is that cybersecurity risks can now directly create clinical risks. A software vulnerability is no longer treated as just an IT problem if it can affect device behavior, delay treatment, expose patient data, or interrupt care.
The FDA also expects manufacturers to look beyond whether a vulnerability can be exploited. What matters equally is the possible impact on patients, healthcare staff, and device functionality. Even a low complexity attack can become serious if it affects a critical medical function.
A proper cybersecurity risk management process should include:
- A documented threat identification process
- Analysis of unauthorized access scenarios
- Evaluation of malware and ransomware risks
- Review of privilege escalation possibilities
- Denial of service risk assessments
- Cloud and remote connectivity risk analysis
- Supplier and third-party security risk reviews
- A defined exploitability scoring method
- Mapping of possible patient harm scenarios
Manufacturers are also expected to implement practical security controls, such as:
- Multi-factor authentication
- Encryption for sensitive data
- Secure boot mechanisms
- Code signing for software integrity
- Network segmentation to limit attack spread
The FDA usually looks for clear evidence showing how these controls reduce both cybersecurity risk and patient safety risk.
3. Create a Medical Device Threat Model
Threat modeling has become a major focus during FDA cybersecurity reviews. Regulators want to see that manufacturers understand how attackers could target the device, move through connected systems, and misuse weak points inside the architecture.
This process is not limited to finding vulnerabilities. It also helps teams understand how a cyberattack could affect device behavior, patient safety, and clinical operations. Because of this, the FDA increasingly expects detailed attack path analysis, architecture reviews, and data flow mapping during development.
Many manufacturers use established Medical Device threat modeling methods, such as:
- STRIDE
- Attack Trees
- PASTA
- MITRE ATT&CK
- MITRE ATLAS for AI-based systems
A medical device threat model should clearly identify important assets, including:
- Firmware
- APIs
- Protected health information
- Cloud services
- Wireless communication interfaces
All possible entry points should also be documented, such as:
- USB ports
- Bluetooth connections
- WiFi communication
- Web portals
- Remote access interfaces
Along with this, manufacturers should map trust boundaries, document abuse cases, and review realistic attack scenarios.
4. Generate an FDA-compliant SBOM
The FDA now expects manufacturers to have clear visibility into every software component used inside a medical device. This is one of the main reasons SBOMs have become such an important part of cybersecurity reviews. If a vulnerability appears in a third-party library, manufacturers should be able to quickly identify whether their device is affected.
An SBOM is no longer treated like optional supporting documentation. In many submissions, it has become a core requirement tied directly to software supply chain security and vulnerability management.
The FDA also expects SBOM management to continue after product release. Maintaining an outdated SBOM creates problems during vulnerability investigations, patching, and postmarket monitoring.
A proper FDA-compliant SBOM should include:
- All software components used in the device
- Open source dependencies
- Commercial software libraries
- Component versions
- Supplier or vendor details
- Dependency relationships between components
- Known vulnerabilities linked to components
- Software licensing information
Most manufacturers structure their SBOMs using formats such as SPDX, CycloneDX, and SWID. The process should also include continuous SBOM monitoring and a defined workflow for analyzing how newly discovered vulnerabilities may affect the device.
5. Conduct Security Testing and Validation
Many medical device teams still depend heavily on automated scans during security reviews. The problem is that automated tools only catch part of the picture. A device may pass a scan and still contain weaknesses that attackers can exploit in real environments.
That is why the FDA expects proper security validation before release. Manufacturers should be able to show how the device was tested, what risks were discovered, and how those issues were addressed. Testing usually includes:
- Internal penetration testing
- Independent third-party testing
- Black box testing
- White box testing
- CVE scanning
- Dependency analysis
- Container security testing
- Hardcoded credential checks
- Encryption validation
Fuzz testing is commonly performed on:
- Communication protocols
- Embedded parsers
- Data processing modules
Manufacturers should also test authentication workflows, MFA controls, and role-based access permissions.
The final security reports should clearly document the testing scope, identified vulnerabilities, risk severity, and remediation status before the device moves toward release or FDA submission.
6. Implement Coordinated Vulnerability Disclosure (CVD)
If someone finds a security issue in your medical device, there should be a proper way to report it. The FDA now expects manufacturers to have a public vulnerability disclosure process instead of handling security reports informally.
Your CVD process should include:
- A public vulnerability disclosure policy
- A dedicated security email or reporting channel
- A documented intake and triage process
- Defined timelines for responding to researchers
- A process for CVE assignment and tracking
- Coordination steps with CISA when necessary
- Internal escalation procedures for serious vulnerabilities
- Approval workflows before public disclosure
The goal is simple. Vulnerabilities should be reported, reviewed, fixed, and communicated in a structured way before they turn into larger security incidents.
7. Develop a Postmarket Vulnerability Management Plan
Finding vulnerabilities after release is normal. What matters is how quickly and properly they are handled. The FDA expects manufacturers to keep monitoring devices even after they are deployed in hospitals or healthcare environments.
Your postmarket vulnerability management plan should include:
- A defined CVE monitoring process
- Threat intelligence feed integration
- Monitoring of the CISA KEV catalog
- Vendor and supplier advisory tracking
- A severity scoring method
- Exploitability assessment workflows
- Patient safety impact analysis
- Patch prioritization procedures
- Hotfix deployment steps
- Customer notification procedures
- Field safety advisory workflows
These activities not only improve device security but also help manufacturers maintain FDA 510(k) compliance by ensuring that cybersecurity risks are continuously monitored and addressed after market release.
8. Secure Software Update Mechanisms
Software updates are one of the easiest ways for attackers to target connected devices. If the update process is weak, someone can push modified firmware or install malicious code inside the device. The FDA specifically looks at how manufacturers protect firmware updates and prevent unauthorized changes.
Your update mechanism should include:
- Digitally signed updates
- Integrity checks before installation
- Rollback protection against downgrade attacks
- Documented OTA security controls
- Authentication for update requests
- Secure delivery channels
- Firmware authenticity verification
Manufacturers should also document how updates are validated before deployment so security fixes do not create new safety or performance issues.
9. Ensure Authentication and Access Control
Weak access controls make medical devices easier to compromise. Shared accounts, poor password policies, and unrestricted permissions are still common problems in connected healthcare systems. The FDA expects manufacturers to limit who can access the device and what actions they can perform.
Important access control measures include:
- MFA for privileged accounts
- Unique user identification
- Defined password complexity requirements
- Role-based access control
- Least privilege access enforcement
- Session timeout controls
- Secure boot protection
- Hardware root of trust implementation
- TPM or HSM integration documentation
10. Encrypt Sensitive Data
Patient data moves through multiple systems inside connected medical devices. If that data is not encrypted properly, attackers can intercept it during transmission or extract it directly from the device. The FDA expects manufacturers to protect both stored data and network communication.
Your encryption controls should cover:
- AES 256 encryption for stored data
- Secure storage of cryptographic keys
- TLS 1.2 or higher for transmitted data
- Certificate validation checks
- Protection for PHI transfers
- Encrypted cloud communication validation
11. Secure Third-Party Components and Suppliers
A lot of medical device vulnerabilities now come from third-party software, open source packages, or supplier-provided components. That is one reason the FDA started paying much closer attention to software supply chain risks in 2026. A single vulnerable dependency inside the device can create serious security and patient safety problems.
Manufacturers should have controls for:
- Vendor security assessments
- Software provenance verification
- Open source governance policies
- Dependency management workflows
- Supplier vulnerability SLAs
- Third-party SBOM verification
12. Prepare FDA Premarket Cybersecurity Documentation
Poor cybersecurity documentation is one of the biggest reasons medical device submissions get delayed. The FDA Premarket Cybersecurity now expects detailed, structured evidence instead of broad security statements. This is especially important for eSTAR submissions, where cybersecurity sections require specific supporting artifacts and documentation.
Your premarket cybersecurity documentation should include:
- Cybersecurity management plan
- Threat model documentation
- Security architecture diagrams
- Security testing reports
- Software Bill of Materials (SBOM)
- Cybersecurity risk assessment report
- Patch and update procedures
- Coordinated Vulnerability Disclosure policy
- Security-related labeling documentation
- Traceability matrix
- Postmarket monitoring plan
The FDA also checks whether these documents align with each other. For example, vulnerabilities identified in the threat model should connect with testing evidence, risk assessments, and mitigation controls documented in the submission.
Talk to our cybersecurity experts for medical device penetration testing
Secure Your Medical Devices with Qualysec
FDA Cybersecurity Documentation Checklist
| Document | Purpose | Required? | FDA Focus Area |
| SBOM | Tracks software components and dependencies | Yes | Third party risk |
| Threat Model | Identifies attack paths and security gaps | Yes | Architecture security |
| Risk Management Report | Documents cybersecurity risk analysis | Yes | Patient safety |
| Penetration Test Report | Shows how the device responds to real attack scenarios | Strongly Expected | Security validation |
| Architecture Diagrams | Maps system communication and trust boundaries | Yes | Secure design |
| Patch Management Plan | Explains how vulnerabilities and updates will be handled | Yes | Lifecycle security |
| CVD Policy | Defines the vulnerability disclosure process | Yes | Coordinated response |
| Security Testing Evidence | Validates implemented security controls | Yes | Verification |
| Traceability Matrix | Connects risks, controls, and testing evidence | Strongly Expected | Compliance evidence |
FDA Refuses to Accept (RTA) Risks
Cybersecurity gaps can delay FDA review much faster now than they did a few years ago. The FDA has already started rejecting or pausing submissions when important cybersecurity documentation is incomplete or missing, especially for 510(k), PMA, and De Novo applications.
Some of the most common cybersecurity-related RTA triggers include:
- Missing SBOM documentation
- Incomplete threat models
- Weak or missing security testing evidence
- No postmarket vulnerability management plan
- Poor traceability between risks, controls, and testing
- Missing update or patch procedures
- Generic cybersecurity summaries without technical evidence
For example, some manufacturers submit penetration testing reports without linking the findings to risk mitigation controls. Others provide architecture diagrams but fail to document trust boundaries or attack paths properly. In many cases, reviewers ask for additional clarification because the submitted evidence does not fully support the claimed security controls.
Mapping FDA Cybersecurity Requirements to Industry Standards
FDA cybersecurity reviews are closely tied to internationally recognized security and quality standards. Most manufacturers use these frameworks to structure development, risk management, testing, and postmarket security processes.
| FDA Expectation | Industry Standard |
| Risk Management | ISO 14971 |
| Secure Development | IEC 81001 5 1 |
| Software Lifecycle | IEC 62304 |
| Vulnerability Disclosure | ISO 29147 |
| Vulnerability Handling | ISO 30111 |
| Healthcare Security Risk Management | AAMI TIR57 |
| Postmarket Security | AAMI TIR97 |
Using these standards helps manufacturers build stronger cybersecurity documentation and align more closely with FDA review expectations during submissions.
How Qualysec Helps Medical Device Manufacturers Strengthen FDA Cybersecurity Readiness
FDA cybersecurity reviews now require detailed testing evidence, not just generic security claims. Manufacturers are expected to prove that vulnerabilities were identified, validated, and properly addressed before submission.
Qualysec helps medical device companies prepare for these requirements through Human Led, AI-Powered penetration testing. Their approach combines automated scanning, AI-driven analysis, and manual security validation to improve both testing speed and accuracy.
Qualysec supports manufacturers with:
- Medical device penetration testing
- API security testing
- IoT security assessments
- Cloud security validation
- Threat modeling support
Their reports include severity-based findings, reproduction steps, remediation guidance, and retesting support after fixes. Independent testing also helps manufacturers strengthen FDA cybersecurity documentation, identify exploitable vulnerabilities earlier, and improve postmarket security readiness before product submission.
Need help with medical device FDA cybersecurity compliance? Schedule a call with our cybersecurity expert today!
Consult with our cybersecurity experts
Discuss your unique security requirements and discover how we can help your business.
Conclusion
Medical device cybersecurity has become much bigger than a last-minute compliance task. The FDA now expects manufacturers to show how security is handled from development to deployment and even after the device reaches hospitals and patients.
That means having a secure development process, proper threat models, updated SBOMs, postmarket vulnerability handling procedures, and real security validation evidence ready during review. Reviewers also expect documentation that actually supports the claims made in the submission. Missing evidence, weak testing, or incomplete risk analysis can slow the process quickly.
Teams that start cybersecurity planning early usually avoid many of these problems later. More importantly, stronger security practices help reduce patient risk and improve the long-term safety of connected medical devices.
FAQs
Q.What is the FDA cybersecurity checklist for medical devices?
Think of it as a preparation checklist for FDA review. It covers the cybersecurity areas manufacturers are expected to handle before launching a connected medical device in the US. That usually includes threat modeling, security testing, SBOM management, software updates, vulnerability handling, and postmarket monitoring.
Q.What are the key cybersecurity requirements in FDA submissions?
The FDA mainly wants proof. Companies are expected to submit documents that show how security risks were identified, tested, and managed. Common examples include SBOMs, threat models, penetration testing reports, architecture diagrams, patch procedures, and risk assessment reports.
Q.Is cybersecurity mandatory for FDA 510(k) approval?
For many connected devices, yes. If the product uses software, network connectivity, wireless communication, cloud functionality, or remote access, cybersecurity requirements are now a major part of the review process.
Q.How do manufacturers perform an FDA-compliant risk assessment?
Most teams start by identifying possible attack scenarios and then evaluating how those risks could affect device functionality or patient safety. The assessment usually connects cybersecurity risks with clinical impact and mitigation controls.
Q.What documents are required for FDA cybersecurity compliance?
Manufacturers commonly prepare documents such as an SBOM, threat model, cybersecurity management plan, penetration testing reports, postmarket monitoring plan, architecture diagrams, and security risk assessment documentation.
0 Comments